Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1767861 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL690750 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL8675920 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL615639 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL4741906 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL1929473 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| Acetic Acid SCHEMBL3260062 | 1.00 | CPB2 (0.53) | CPB2CA2GRIK1GRIK2GPR84 | |
| SCHEMBL25341592 | 0.94 | CPB2 (0.58) | CPB2CA2GRIK1GRIK2GPR84 | |
| SCHEMBL571313 | 0.94 | CPB2 (0.58) | CPB2CA2GRIK1GRIK2GPR84 | |
| SCHEMBL19148651 | 0.94 | CPB2 (0.58) | CPB2CA2GRIK1GRIK2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415468-B | Electro-optical polymers | 国立研究开发法人情报通信研究机构 | 2024-06-07 | — | — | CN | disclosed |
| CN-118126046-A | Substituted macrocyclic compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-113264967-B | Programmed death ligand-1 targeted compound and preparation method and application thereof | 江苏省原子医学研究所 | 2023-04-18 | — | — | CN | disclosed |
| EP-2955181-B1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| CN-109415468-A | Electrooptics polymer | 国立研究开发法人情报通信研究机构 | 2019-03-01 | — | — | CN | disclosed |
| EP-3081553-B1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIV TSUKUBA (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-9815787-B2 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2017-11-14 | — | — | US | disclosed |
| EP-2704246-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTRICAL STORAGE DEVICE UTILIZING SAME, AND CYCLIC SULFONIC ACID ESTER COMPOUND | UBE INDUSTRIES (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-9608287-B2 | Non-aqueous electrolytic solution, electrical storage device utilizing same, and cyclic sulfonic acid ester compound | UBE INDUSTRIES, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2016-12-15 | — | — | US | disclosed |
| EP-0412542-A2 | Cyclic neurokinin antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-02-13 | — | — | EP | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4918170-A | Process for producing gangliosides | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0353474-A2 | Glycerin derivative and its pharmacological use | Eisai Co., Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| CN-1039414-A | Glycerol derivatives and pharmaceutical use thereof | EISAI CO LTD (JP) | 1990-02-07 | — | — | CN | disclosed |
| EP-0347802-A2 | Neurokinin A antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| US-4734418-A | Quinazoline compounds and antihypertensives | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| EP-0188094-A2 | Quinazoline derivatives and antihypertensive preparations containing same as effective components | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | CPB2 2871/4885CA2 226/4885GRIK1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.